Advisory Board

Scott Antonia, MD, PhD
Scott Antonia, MD, PhD
Clinical Advisor

Mr. Antonia is a Director at the Center for Cancer Immunotherapy at Duke University.

Tanios Bekaii-Saab, MD
Tanios Bekaii-Saab, MD
Clinical Advisor

Tanios Bekaii-Saab, MD: Dr. Bekaii-Saab conducts clinical and translational research focused on developing anti-cancer agents for patients with gastrointestinal cancers. Dr. Bekaii-Saab collaborates extensively with various scientists and industry partners to design and execute innovative clinical trials, including many first-in-human studies. He also leads the Mayo Clinic supported cancer research consortium Academic and Community Cancer Research United (ACCRU) and is one of the leading clinician-scientists in the Alliance for Clinical Trials in Oncology, a National Cancer Institute (NCI)-supported cooperative research group.

Scott Kopetz, MD, PhD, FACP
Scott Kopetz, MD, PhD, FACP
Clinical Advisor

Dr. Kopetz is a Professor in the Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center. He is a physician-scientist who enjoys the intellectual challenges of the lab, the emotional engagement of the clinic and has the motivation to bridge the two.

Gilberto de Lima Lopes Jr, MD, MBA, FAMS
Gilberto de Lima Lopes Jr, MD, MBA, FAMS
Clinical Advisor

Dr. de Lima Lopes is Chair of Oncology and Associate Professor of Clinical Medicine at the University of Miami and works on developing new drugs to treat cancer as well as designing, leading and participating in Phase I through IV clinical trials. He has helped bring novel cancer therapies into the clinic. He is also a leader in the area known as Global Oncology and is the Editor for the Journal of Global Precision Oncology.

Daniel F. Hayes, MD, FASCO, FACP
Daniel F. Hayes, MD, FASCO, FACP
Clinical Advisor

Dr. Hayes is the Stuart B. Padnos Professor in Breast Cancer at the University of Michigan Rogel Cancer Center. He served as the past President of ASCO from 2015 to 2018 and is a world recognized thought leader in the field.

Mike Varney, PhD
Mike Varney, PhD
Science Advisor

Dr. Varney is a consultant for the pharmaceutical and biotech community. He focuses on Drug Discovery, Drug Development and Strategic advising.

William A. Hawkins
William A. Hawkins
Business Advisor

Mr. Hawkins is former Chairman and CEO of Medtronic as well as a current and active board member on public, private and not-for-profit boards. He is a Senior Advisor to EW Healthcare partners and Vice Chair of the Duke Board of Trustees and Chair of the Board of the Duke University Health System.

David C. Heimbrook, PhD
David C. Heimbrook, PhD
Business Advisor

Dr. Heimbrook received his BA degree from Duke University and his PhD in Biochemistry from Yale University. He brings over 30 years experience in cancer research and drug discovery, and recently retired from his position leading Frederick National Laboratory for Cancer Research, a Federally Funded Research and Development Center (FFRDC) sponsored by the National Cancer Institute (NCI).